Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATTAIN-PAD
NL-OMON60586Phase 3Not yet recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in arteriosclerosis obliterans comparing Orforglipron with Placebo (2 arms). Primary endpoint: Percent change from baseline in maximum walking distance on a constant load treadmill test. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
orforglipron
03
Conditions
arteriosclerosis obliterans
Beyond the preview
Go deeper on NL-OMON60586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60586.